Literature DB >> 33663561

Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction.

Emma M Perkins1,2,3, Karen Burr1,2,4, Poulomi Banerjee2,4, Arpan R Mehta1,2,4, Owen Dando3,4,5, Bhuvaneish T Selvaraj1,2,4, Daumante Suminaite3, Jyoti Nanda1,2,4, Christopher M Henstridge1,6, Thomas H Gillingwater1,3, Giles E Hardingham3,4,5, David J A Wyllie3,5,7, Siddharthan Chandran8,9,10,11,12, Matthew R Livesey13,14,15,16.   

Abstract

BACKGROUND: Physiological disturbances in cortical network excitability and plasticity are established and widespread in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those harbouring the C9ORF72 repeat expansion (C9ORF72RE) mutation - the most common genetic impairment causal to ALS and FTD. Noting that perturbations in cortical function are evidenced pre-symptomatically, and that the cortex is associated with widespread pathology, cortical dysfunction is thought to be an early driver of neurodegenerative disease progression. However, our understanding of how altered network function manifests at the cellular and molecular level is not clear.
METHODS: To address this we have generated cortical neurons from patient-derived iPSCs harbouring C9ORF72RE mutations, as well as from their isogenic expansion-corrected controls. We have established a model of network activity in these neurons using multi-electrode array electrophysiology. We have then mechanistically examined the physiological processes underpinning network dysfunction using a combination of patch-clamp electrophysiology, immunocytochemistry, pharmacology and transcriptomic profiling.
RESULTS: We find that C9ORF72RE causes elevated network burst activity, associated with enhanced synaptic input, yet lower burst duration, attributable to impaired pre-synaptic vesicle dynamics. We also show that the C9ORF72RE is associated with impaired synaptic plasticity. Moreover, RNA-seq analysis revealed dysregulated molecular pathways impacting on synaptic function. All molecular, cellular and network deficits are rescued by CRISPR/Cas9 correction of C9ORF72RE. Our study provides a mechanistic view of the early dysregulated processes that underpin cortical network dysfunction in ALS-FTD.
CONCLUSION: These findings suggest synaptic pathophysiology is widespread in ALS-FTD and has an early and fundamental role in driving altered network function that is thought to contribute to neurodegenerative processes in these patients. The overall importance is the identification of previously unidentified defects in pre and postsynaptic compartments affecting synaptic plasticity, synaptic vesicle stores, and network propagation, which directly impact upon cortical function.

Entities:  

Keywords:  ALS; C9ORF72; Cortical; Electrophysiology; FTD; Hyperexcitability; Network; Neuron; Repeat expansion; Synaptic

Mesh:

Substances:

Year:  2021        PMID: 33663561      PMCID: PMC7931347          DOI: 10.1186/s13024-021-00433-8

Source DB:  PubMed          Journal:  Mol Neurodegener        ISSN: 1750-1326            Impact factor:   14.195


  66 in total

Review 1.  Alzheimer's Disease: From Firing Instability to Homeostasis Network Collapse.

Authors:  Samuel Frere; Inna Slutsky
Journal:  Neuron       Date:  2018-01-03       Impact factor: 17.173

2.  C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Yoshitsugu Aoki; Raquel Manzano; Yi Lee; Ruxandra Dafinca; Misako Aoki; Andrew G L Douglas; Miguel A Varela; Chaitra Sathyaprakash; Jakub Scaber; Paola Barbagallo; Pieter Vader; Imre Mäger; Kariem Ezzat; Martin R Turner; Naoki Ito; Samanta Gasco; Norihiko Ohbayashi; Samir El Andaloussi; Shin'ichi Takeda; Mitsunori Fukuda; Kevin Talbot; Matthew J A Wood
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

3.  Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis.

Authors:  Bahman Nasseroleslami; Stefan Dukic; Michael Broderick; Kieran Mohr; Christina Schuster; Brighid Gavin; Russell McLaughlin; Mark Heverin; Alice Vajda; Parameswaran M Iyer; Niall Pender; Peter Bede; Edmund C Lalor; Orla Hardiman
Journal:  Cereb Cortex       Date:  2019-01-01       Impact factor: 5.357

Review 4.  Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease.

Authors:  Austen J Milnerwood; Lynn A Raymond
Journal:  Trends Neurosci       Date:  2010-09-17       Impact factor: 13.837

5.  Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6.

Authors:  A Charest; K Lane; K McMahon; D E Housman
Journal:  J Biol Chem       Date:  2001-05-30       Impact factor: 5.157

6.  Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis.

Authors:  P Menon; N Geevasinga; M van den Bos; C Yiannikas; M C Kiernan; S Vucic
Journal:  Eur J Neurol       Date:  2017-04-24       Impact factor: 6.089

7.  Cortical hyperexcitability in patients with C9ORF72 mutations: Relationship to phenotype.

Authors:  Olivia Schanz; Devin Bageac; Laura Braun; Bryan J Traynor; Tanya J Lehky; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2016-05-25       Impact factor: 3.217

8.  Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain.

Authors:  Ramesh K Narayanan; Marie Mangelsdorf; Ajay Panwar; Tim J Butler; Peter G Noakes; Robyn H Wallace
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2012-10-24       Impact factor: 4.092

9.  Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability.

Authors:  Anna-Claire Devlin; Karen Burr; Shyamanga Borooah; Joshua D Foster; Elaine M Cleary; Imbisaat Geti; Ludovic Vallier; Christopher E Shaw; Siddharthan Chandran; Gareth B Miles
Journal:  Nat Commun       Date:  2015-01-12       Impact factor: 14.919

10.  Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment.

Authors:  Brigid K Jensen; Martin H Schuldi; Kevin McAvoy; Katelyn A Russell; Ashley Boehringer; Bridget M Curran; Karthik Krishnamurthy; Xinmei Wen; Thomas Westergard; Le Ma; Aaron R Haeusler; Dieter Edbauer; Piera Pasinelli; Davide Trotti
Journal:  EMBO Mol Med       Date:  2020-04-29       Impact factor: 12.137

View more
  12 in total

Review 1.  Phase separation of low-complexity domains in cellular function and disease.

Authors:  Jiwon Lee; Hana Cho; Ilmin Kwon
Journal:  Exp Mol Med       Date:  2022-09-29       Impact factor: 12.153

2.  Aging-Dependent Altered Transcriptional Programs Underlie Activity Impairments in Human C9orf72-Mutant Motor Neurons.

Authors:  Daniel Sommer; Sandeep Rajkumar; Mira Seidel; Amr Aly; Albert Ludolph; Ritchie Ho; Tobias M Boeckers; Alberto Catanese
Journal:  Front Mol Neurosci       Date:  2022-06-14       Impact factor: 6.261

3.  Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis.

Authors:  Sai Zhang; Johnathan Cooper-Knock; Annika K Weimer; Minyi Shi; Tobias Moll; Jack N G Marshall; Calum Harvey; Helia Ghahremani Nezhad; John Franklin; Cleide Dos Santos Souza; Ke Ning; Cheng Wang; Jingjing Li; Allison A Dilliott; Sali Farhan; Eran Elhaik; Iris Pasniceanu; Matthew R Livesey; Chen Eitan; Eran Hornstein; Kevin P Kenna; Jan H Veldink; Laura Ferraiuolo; Pamela J Shaw; Michael P Snyder
Journal:  Neuron       Date:  2022-01-18       Impact factor: 18.688

Review 4.  Emerging Mechanisms Underpinning Neurophysiological Impairments in C9ORF72 Repeat Expansion-Mediated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.

Authors:  Iris-Stefania Pasniceanu; Manpreet Singh Atwal; Cleide Dos Santos Souza; Laura Ferraiuolo; Matthew R Livesey
Journal:  Front Cell Neurosci       Date:  2021-12-15       Impact factor: 5.505

5.  Selective vulnerability of tripartite synapses in amyotrophic lateral sclerosis.

Authors:  Matthew J Broadhead; Calum Bonthron; Julia Waddington; William V Smith; Maite F Lopez; Sarah Burley; Jessica Valli; Fei Zhu; Noboru H Komiyama; Colin Smith; Seth G N Grant; Gareth B Miles
Journal:  Acta Neuropathol       Date:  2022-03-19       Impact factor: 15.887

6.  Poly-dipeptides produced from C9orf72 hexanucleotide repeats cause selective motor neuron hyperexcitability in ALS.

Authors:  Yunhee Jo; Jiwon Lee; Seul-Yi Lee; Ilmin Kwon; Hana Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-08       Impact factor: 11.205

Review 7.  Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches.

Authors:  Nadine Huber; Sonja Korhonen; Dorit Hoffmann; Stina Leskelä; Hannah Rostalski; Anne M Remes; Paavo Honkakoski; Eino Solje; Annakaisa Haapasalo
Journal:  Mol Psychiatry       Date:  2021-11-19       Impact factor: 13.437

8.  Synaptopathy in CHMP2B frontotemporal dementia highlights the synaptic vesicle cycle as a therapeutic target.

Authors:  Miranda Robbins; Emma L Clayton
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

9.  SPG15 protein deficits are at the crossroads between lysosomal abnormalities, altered lipid metabolism and synaptic dysfunction.

Authors:  Lara Marrone; Paolo M Marchi; Christopher P Webster; Raffaele Marroccella; Ian Coldicott; Steven Reynolds; João Alves-Cruzeiro; Zih-Liang Yang; Adrian Higginbottom; Mukhran Khundadze; Pamela J Shaw; Christian A Hübner; Matthew R Livesey; Mimoun Azzouz
Journal:  Hum Mol Genet       Date:  2022-08-23       Impact factor: 5.121

10.  An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD.

Authors:  Claudia S Bauer; Rebecca N Cohen; Francesca Sironi; Matthew R Livesey; Thomas H Gillingwater; J Robin Highley; Daniel J Fillingham; Ian Coldicott; Emma F Smith; Yolanda B Gibson; Christopher P Webster; Andrew J Grierson; Caterina Bendotti; Kurt J De Vos
Journal:  Acta Neuropathol       Date:  2022-07-25       Impact factor: 15.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.